SCHEMBL6323738

SCHEMBL6323738

CN(C(=O)OC(C)(C)C)[C@H](Cc1ccccc1)C(=O)NCCCO

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.46
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
AKT1 P31749 1/20 0.44
MMP13 P45452 1/20 0.44
CCR3 P51677 1/20 0.44
CTSS P25774 3/20 0.42
CTSK P43235 2/20 0.42
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
AAK1 Q2M2I8 1/20 0.39
MMP8 P22894 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318252 0.87 REN (0.44) RENTSHRAKT1MMP13CTSS
SCHEMBL6320048 0.87 REN (0.44) RENTSHRAKT1MMP13CTSS
SCHEMBL11443640 0.85 REN (0.45) RENCYP3A4TSHRAKT1MMP13
SCHEMBL7066319 0.84 CYP3A4 (0.52) CYP3A4TSHRCCR3CYP2D6CYP2C9
SCHEMBL4426560 0.83 REN (0.50) RENAKT1MMP13CTSSCTSK
SCHEMBL6319222 0.83 REN (0.47) RENCYP3A4TSHRAKT1MMP13
SCHEMBL11436901 0.83 REN (0.44) RENCYP3A4TSHRAKT1MMP13
SCHEMBL3268116 0.82 REN (0.49) RENAKT1MMP13CTSSCTSK
SCHEMBL3268094 0.82 REN (0.49) RENAKT1MMP13CTSSCTSK
SCHEMBL6600189 0.82 REN (0.49) RENAKT1MMP13CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 REN 261/4885CYP3A4 3623/4885TSHR 63/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR REN 263/4885CYP3A4 3566/4885TSHR 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.